RxDoctor Payments DataLook up a doctor →

Kelley Beltran

Family · Milwaukee, WINPI 1063949600

Payments from drug & device makers

$9,441in general payments, 2019–2025

Across 545 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Bayer$754
  • Lilly USA, LLC$718
  • Pfizer$537
  • Phathom Pharmaceuticals, Inc.$396
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$9,37699%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,441 in reported general payments places this provider in the 95th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$12,300
Medicare patients
38
Services billed
247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide86$92,280
OzempicSemaglutide57$74,933
TrulicityDulaglutide47$59,120
FarxigaDapagliflozin Propanediol51$49,618
LinzessLinaclotide73$48,658
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$48,266
UbrelvyUbrogepant21$35,700
Nurtec OdtRimegepant Sulfate30$34,230
TradjentaLinagliptin20$24,517
KerendiaFinerenone26$24,102
JanuviaSitagliptin Phosphate24$23,240
RybelsusSemaglutide12$19,702
JanumetSitagliptin Phos/Metformin Hcl23$15,895
SymbicortBudesonide/Formoterol Fumarate59$15,352
Spiriva HandihalerTiotropium Bromide23$14,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$718$151,400133 claims
AbbVieLinzess, Ubrelvy, Restasis$2,291$96,286113 claims
Novo NordiskOzempic, Rybelsus$200$94,63669 claims
AstraZenecaFarxiga, Symbicort$1,436$64,970110 claims
GSKTrelegy Ellipta, Arnuity Ellipta$127$51,88082 claims
MerckJanuvia, Janumet, Belsomra$99$44,87060 claims
Boehringer IngelheimTradjenta, Jardiance, Spiriva Respimat$116$41,18645 claims
PfizerNurtec Odt$537$34,23030 claims
BayerKerendia$754$24,10226 claims
Astellas Pharma US IncMyrbetriq$291$12,76120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,273 family providers in Wisconsin.

Other family in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →